> "Most of the active projects are in exploratory or preclinical stages. However, 5 candidates have recently moved into clinical development, including mRNA-1273 (Moderna), Ad5-nCoV (CanSino Biologicals), INO-4800 (Inovio), LV-SMENP-DC and pathogen-specific aAPC (Shenzhen Geno-Immune Medical Institute). Notably, Moderna was able to start clinical testing of its mRNA-based vaccine just 63 days after sequence identification."
Presumably, those are 5 out of the 8-10 that Gates thinks is promising
[1]: https://cepi.net/news_cepi/cepi-publishes-analysis-of-covid-...